- Introduces Novaplex™ MPXV/OPXV plus Assay (RUO) that is
designed to detect Clade I, which has higher transmission and
mortality rates than Clade II
- Adheres to the WHO issued target product profiles and provides
accurate detection of viral strains
- Offers healthcare professionals with a critical tool in their
research on the global spread of mpox by supporting
international efforts
SEOUL, South Korea,
Sept. 9, 2024 /PRNewswire/ -- Seegene
Inc., a leading provider of total solution for PCR molecular
diagnostics based in South Korea,
announced today that it will introduce a new type of
research-use-only (RUO) PCR assay to address the spread of the mpox
virus variant, Clade Ib, which is currently prevalent in
Africa.
The newly introduced Novaplex™ MPXV/OPXV plus Assay (RUO)
is designed to detect 3 targets causing mpox disease: non-variola
Orthopoxvirus (OPXV) and mpox virus (MPVX) with specific
confirmation of MPXV Clade I. MPXV Clade I is associated with
higher transmission and mortality rates than MPXV Clade
II.
The assay meets the preferred target product profiles (TPPs)
issued by the WHO, which guide manufacturers, suppliers, and
researchers developing new assays for detection of viruses causing
mpox. Additionally, it aligns with the preferred target analyte
criteria for distinguishing between Clade I and II.
Seegene has been responding swiftly to the August 2024 global public health emergency
(PHEIC) declared by the WHO regarding the mpox outbreak by
developing two assays designed to detect mpox virus and announcing
plans to supply the products to countries in need.
Among these, Novaplex™ MPXV/OPXV Assay (RUO) is designed to
detect MPXV Clade I and Clade II as well as OPXV infections, while
Novaplex™ HSV-1&2/VZV/MPXV Assay (RUO) is designed to
simultaneously detect four viruses including MPXV, herpes simplex
virus (HSV) Types 1 and 2, and varicella-zoster virus (VZV). These
products also comply with TPPs issued by the WHO.
"As the spread of mpox continues unabated, we have developed new
RUO assays for detection of viruses causing the mpox to meet the
increasing research demand from affected countries. We are
committed to actively supporting global efforts to curb the spread
of mpox," said Daniel Shin,
Executive Vice-President and Chief Global Sales and Marketing
Officer at Seegene.
In 2022, Seegene had previously leveraged its proprietary
reagent development expertise and automated reagent development
system (SGDDS) to create the Novaplex™ MPXV Assay (RUO).
From January 2024 to September 6, 2024, there have been a total of
24,851 suspected cases, 5,549 confirmed cases and 643 deaths
reported across the member states in the African Union (AU),
according to the Africa Centres for Disease Control and Prevention
(Africa CDC). The mpox variant is now spreading beyond African
countries including Sweden,
Pakistan, the Philippines, Jordan and Thailand.
About Seegene
Seegene has 23 years of dedicated experience in R&D,
manufacturing, and business related to multiplex PCR technologies.
This expertise was particularly highlighted during the COVID-19
pandemic when Seegene provided over 340 million COVID-19 tests to
more than 100 countries worldwide. The core feature of Seegene's
multiplex PCR technology is the ability to simultaneously test for
14 pathogens that cause similar symptoms in a single tube and
provide quantitative information on the infection profile to
correlate with the progression of illness.
Visit: Seegene.com and
follow linkedin.com/company/seegene-inc
Photo -
https://mma.prnewswire.com/media/2499983/Photo__Seegene_Expands_mpox_RUO_Product_Lineups_with_Enhanced_Detection_Assays_for_Clade_1.jpg
Logo -
https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/seegene-expands-mpox-ruo-product-lineups-with-enhanced-detection-assays-for-clade-1-302242213.html